Navigation Links
BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results
Date:2/2/2009

SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced it will report results for its fourth quarter and year ended December 31, 2008 after the market closes on Wednesday, February 11, 2009.

Alan D. Gold, Chairman and Chief Executive Officer, and Kent Griffin, President and Chief Financial Officer, will host an investor conference call at 10:00 a.m. Pacific Time on Thursday, February 12, 2009 to discuss the company's financial results and operations for the year.

The call will be open to all interested investors either through a live audio web cast at the Investor Relations section of the company's web site at www.biomedrealty.com and at www.earnings.com, or live by calling 800.299.7089 (domestic) or 617.801.9714 (international) with call ID number 80976360. The call will be archived for 30 days on both web sites. A telephone playback of the conference call will also be available from 3:00 p.m. Pacific Time on Thursday, February 12, 2009 through midnight Pacific Time on Tuesday, February 17, 2009 by calling 888.286.8010 (domestic) or 617.801.6888 (international) and using access code 78309388.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.4 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
2. Origin BioMed Awarded Red Herring Top 100 Global Company
3. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
4. Bavarian Nordics Case Against Oxford BioMedica
5. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
6. BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends
7. BioMed Realty Trust Promotes Kent Griffin to President
8. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
9. BioFlorida Selects Collexis BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations
10. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
11. SpineSmith Partners Collaborates with University of Texas Biomedical Engineering Students to Develop Innovative Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm ... its continued commitment to the advancement of the clinical trials segment. Hosted in ... to clinical trial planning and management. , As executive talent specialists in ...
(Date:1/18/2017)... NY (PRWEB) , ... January 18, 2017 , ... Researchers from a new study ... do not fall low enough after prostate cancer treatment, this indicates there is still remaining ... risk of mortality. , “ The PSA test has always been an indicator of whether ...
(Date:1/18/2017)... , Jan. 18, 2017 Shareholder rights law ... into whether the board members of CoLucid Pharmaceuticals, Inc. ... in connection with the proposed sale of the Company ... company that develops small molecules for the acute treatment ... announced it had signed a definitive merger agreement with ...
(Date:1/17/2017)... ... January 17, 2017 , ... LGC ... to its VALIDATE® SP2 calibration verification / linearity test kit. VALIDATE® SP2 evaluates ... Each VALIDATE® SP2 kit is prepared using the CLSI recommended “equal delta” method ...
Breaking Biology Technology:
(Date:12/16/2016)... 2016 Research and Markets has announced the ... Forecast to 2021" report to their offering. ... The biometric vehicle access system ... CAGR of 14.06% from 2016 to 2021. The market is estimated ... reach 854.8 Million by 2021. The growth of the biometric vehicle ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much more ... or starting the engine. Continental will demonstrate the intelligence ... Las Vegas . Through the combination of the ... Entry) and biometric elements, the international technology company is ... personalization and authentication. "The integration of biometric ...
Breaking Biology News(10 mins):